Legislative Update Strengthens Orphan Drug Act, Boosts Innovation for Rare Disease Treatments
In February 2026, the pharmaceutical industry witnessed a legislative development with the enactment of the 2026 Consolidated Appropriations Act. This new law addresses longstanding issues within the Orphan Drug Act, providing clarity and incentives for companies engaged in the research and development of orphan drugs, which are crucial for treating rare diseases. This legislative update…